ELITE PHARMACEUTICALS INC /NV/ Quarterly Retained Earnings (Accumulated Deficit) in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q1 2011 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Retained Earnings (Accumulated Deficit) for the quarter ending September 30, 2024 was -$127M, a 5.31% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 -$127M -$6.39M -5.31% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$116M +$19.6M +14.5% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$116M +$20.1M +14.7% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$120M +$15.6M +11.5% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 -$120M +$17.8M +12.9% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$135M +$4.4M +3.15% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 -$136M +$3.56M +2.54% Mar 31, 2023 10-K 2024-07-01
Q4 2022 -$135M +$7.22M +5.07% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 -$138M +$6.53M +4.51% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$140M +$6.82M +4.65% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 -$140M +$8.9M +5.97% Mar 31, 2022 10-K 2023-06-29
Q4 2021 -$142M +$5.99M +4.03% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 -$145M +$5.72M +3.8% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 -$147M +$6.4M +4.18% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 -$149M +$5.09M +3.3% Mar 31, 2021 10-K 2022-06-29
Q4 2020 -$148M +$6.51M +4.2% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 -$150M +$2.63M +1.72% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 -$153M -$1.44M -0.95% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 -$154M -$2.24M -1.48% Mar 31, 2020 10-K 2021-06-14
Q4 2019 -$155M -$5.84M -3.92% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 -$153M -$6.32M -4.31% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 -$152M -$7.31M -5.07% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 -$152M -$9.28M -6.51% Mar 31, 2019 10-K 2020-06-30
Q4 2018 -$149M -$9.45M -6.76% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 -$147M -$7.59M -5.45% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 -$144M -$3.19M -2.26% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 -$143M -$3.67M -2.65% Mar 31, 2018 10-K 2019-06-21
Q4 2017 -$140M -$4.03M -2.97% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 -$139M -$1.87M -1.37% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 -$141M +$548K +0.39% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 -$139M +$3.81M +2.67% Mar 31, 2017 10-K 2018-06-14
Q4 2016 -$136M +$15.5M +10.3% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 -$137M +$1.6M +1.15% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 -$142M -$4.32M -3.15% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 -$143M -$683K -0.48% Mar 31, 2016 10-K 2017-06-14
Q4 2015 -$151M +$35.8M +19.2% Dec 31, 2015 10-Q 2016-02-09
Q3 2015 -$139M +$69.1M +33.2% Sep 30, 2015 10-Q/A 2015-12-30
Q2 2015 -$137M +$92.2M +40.2% Jun 30, 2015 10-Q/A 2015-12-30
Q1 2015 -$142M +$83M +36.9% Mar 31, 2015 10-K 2016-06-15
Q4 2014 -$187M -$48.8M -35.3% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 -$208M -$70.9M -51.7% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 -$229M -$102M -79.9% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 -$225M -$96.6M -75.2% Mar 31, 2014 10-K 2015-06-15
Q4 2013 -$138M -$8.18M -6.29% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 -$137M +$2.24M +1.61% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 -$128M +$12.9M +9.21% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 -$128M +$1.49M +1.15% Mar 31, 2013 10-K 2014-06-30
Q4 2012 -$130M -$7.11M -5.79% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 -$139M -$7.72M -5.86% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 -$140M +$5.15M +3.54% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 -$130M -$15.1M -13.1% Mar 31, 2012 10-K 2013-06-21
Q4 2011 -$123M Dec 31, 2011 10-Q 2012-02-14
Q3 2011 -$132M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 -$146M Jun 30, 2011 10-Q/A 2011-08-19
Q1 2011 -$115M Mar 31, 2011 10-K 2012-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.